Trial
NCT00478062
Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
National Cancer Institute (NCI)
Condition
Lymphoma
Intervention
Hodgkin's antigens-GM-CSF-expressing cell vaccine
Why stopped
Poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-28